Brendan was the first team member engaged full-time on the collaboration between UCLA’s Transitional Oncology Research Lab (TORL) and Brian Stoltz’s group at Caltech. Brendan utilizes in silico computer modeling and cutting-edge chemistry technology to design compounds against multiple challenging targets. One of his compounds became the first drug designed and synthesized at Caltech to enter clinical studies for the treatment of human cancer.
Brendan began his career at Merck Research Labs (MRL) in Boston, followed by several other life science start-ups. Brendan has co-authored approximately twenty patents and publications relevant to chemical synthesis and medicinal chemistry.
Brendan completed his Ph.D. in 2009 with Barry M. Trost at Stanford University.